AU2015315431C1 - Treatment of androgen deprivation therapy associated symptoms - Google Patents

Treatment of androgen deprivation therapy associated symptoms Download PDF

Info

Publication number
AU2015315431C1
AU2015315431C1 AU2015315431A AU2015315431A AU2015315431C1 AU 2015315431 C1 AU2015315431 C1 AU 2015315431C1 AU 2015315431 A AU2015315431 A AU 2015315431A AU 2015315431 A AU2015315431 A AU 2015315431A AU 2015315431 C1 AU2015315431 C1 AU 2015315431C1
Authority
AU
Australia
Prior art keywords
pct
day
dose
symptoms
orx
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015315431A
Other languages
English (en)
Other versions
AU2015315431A1 (en
AU2015315431B2 (en
Inventor
Charles Thomas Benson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eirgen Pharma Ltd
Original Assignee
Eirgen Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eirgen Pharma Ltd filed Critical Eirgen Pharma Ltd
Publication of AU2015315431A1 publication Critical patent/AU2015315431A1/en
Publication of AU2015315431B2 publication Critical patent/AU2015315431B2/en
Priority to AU2018202714A priority Critical patent/AU2018202714B2/en
Application granted granted Critical
Publication of AU2015315431C1 publication Critical patent/AU2015315431C1/en
Assigned to OPKO HEALTH, INC. reassignment OPKO HEALTH, INC. Request for Assignment Assignors: ELI LILLY AND COMPANY
Assigned to EIRGEN PHARMA LTD. reassignment EIRGEN PHARMA LTD. Request for Assignment Assignors: OPKO HEALTH, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Indole Compounds (AREA)
AU2015315431A 2014-09-11 2015-09-08 Treatment of androgen deprivation therapy associated symptoms Active AU2015315431C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018202714A AU2018202714B2 (en) 2014-09-11 2018-04-18 Treatment of androgen deprivation therapy associated symptoms

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462049192P 2014-09-11 2014-09-11
US62/049,192 2014-09-11
PCT/US2015/048801 WO2016040234A1 (en) 2014-09-11 2015-09-08 Treatment of androgen deprivation therapy associated symptoms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018202714A Division AU2018202714B2 (en) 2014-09-11 2018-04-18 Treatment of androgen deprivation therapy associated symptoms

Publications (3)

Publication Number Publication Date
AU2015315431A1 AU2015315431A1 (en) 2017-03-09
AU2015315431B2 AU2015315431B2 (en) 2018-03-08
AU2015315431C1 true AU2015315431C1 (en) 2018-08-02

Family

ID=54151401

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015315431A Active AU2015315431C1 (en) 2014-09-11 2015-09-08 Treatment of androgen deprivation therapy associated symptoms
AU2018202714A Active AU2018202714B2 (en) 2014-09-11 2018-04-18 Treatment of androgen deprivation therapy associated symptoms

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018202714A Active AU2018202714B2 (en) 2014-09-11 2018-04-18 Treatment of androgen deprivation therapy associated symptoms

Country Status (23)

Country Link
US (4) US10758515B2 (https=)
EP (2) EP3375444A1 (https=)
JP (4) JP6893171B2 (https=)
KR (5) KR20170040338A (https=)
CN (4) CN106794178A (https=)
AP (1) AP2017009795A0 (https=)
AU (2) AU2015315431C1 (https=)
BR (2) BR112017002449B1 (https=)
CA (2) CA3067289C (https=)
EA (2) EA034553B1 (https=)
ES (1) ES2779978T3 (https=)
HK (1) HK1252811A1 (https=)
IL (3) IL279209B2 (https=)
JO (2) JOP20180072A1 (https=)
MA (1) MA45416A (https=)
MX (3) MX391447B (https=)
MY (2) MY195767A (https=)
NZ (1) NZ728612A (https=)
SG (2) SG11201701630VA (https=)
TW (1) TWI616201B (https=)
UA (1) UA120099C2 (https=)
WO (1) WO2016040234A1 (https=)
ZA (1) ZA201802680B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20180072A1 (ar) * 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين
US20180185347A1 (en) 2016-11-16 2018-07-05 Transition Therapeutics (Ireland 2) Limited Tetrahydrocyclopenta[b]indole compounds and phosphodiesterase inhibitors for the treatment of the signs and symptoms of bhp
WO2021151905A1 (en) 2020-01-27 2021-08-05 Transition Therapeutics (Ireland 2) Limited Tetrahydrocyclopenta[b]indole compounds for the treatment of renal disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100069404A1 (en) * 2006-11-20 2010-03-18 Konstantinos Gavardinas TETRAHYDROCYCLOPENTA[b] INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2457892A1 (en) * 2003-01-13 2012-05-30 University of Tennessee Research Foundation Large-scale synthesis of selective androgen receptor modulators
US9889110B2 (en) * 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
CA2653872A1 (en) 2006-05-31 2007-12-06 Glaxo Group Limited Novel heterocyclic compounds
CA2658098A1 (en) * 2006-07-19 2008-01-24 Osurf Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
US7443672B2 (en) 2006-10-03 2008-10-28 Fu Zhun Precision Industry (Shen Zhen) Co., Ltd. Video graphics array (VGA) card assembly
TW200918521A (en) * 2007-08-31 2009-05-01 Astrazeneca Ab Heterocyclic amides and methods of use thereof
US8420624B2 (en) 2007-12-04 2013-04-16 Yung Shin Pharm. Ind. Co., Ltd. Methods for treating or preventing symptoms of hormonal variations
KR101595238B1 (ko) 2007-12-21 2016-02-18 리간드 파마슈티칼스 인코포레이티드 선택적 안드로겐 수용체 조절제(ｓａｒｍ) 및 이의 용도
BRPI0912394A2 (pt) * 2008-05-16 2016-07-26 Lilly Co Eli moduladores do receptor de androgênio à base de tetra-hidrociclopenta[b]indol
US8003689B2 (en) * 2008-06-20 2011-08-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
AR078862A1 (es) * 2009-11-13 2011-12-07 Lilly Co Eli Ester isopropilico del acido ((s)-7-ciano-4-((2r,3s)-3-hidroxitetrahidrofuran-2-ilmetil)-1,2,3,4-tetrahidro-ciclopenta(b)indol-2-il)carbamico, composiciones farmaceuticas que lo comprenden y su uso en terapia
CN102234287B (zh) * 2010-04-26 2015-08-05 上海阳帆医药科技有限公司 硝基咪唑类化合物、其制备方法和用途
JP2012149054A (ja) * 2010-12-27 2012-08-09 Dainippon Sumitomo Pharma Co Ltd Ｎ−置換−環状アミノ誘導体からなる医薬
KR102098606B1 (ko) * 2012-10-31 2020-04-09 후지필름 도야마 케미컬 가부시키가이샤 신규 아민 유도체 또는 그 염
US9920052B2 (en) * 2013-12-09 2018-03-20 Ucb Biopharma Sprl Imidazopyridine derivatives as modulators of TNF activity
JOP20180072A1 (ar) * 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100069404A1 (en) * 2006-11-20 2010-03-18 Konstantinos Gavardinas TETRAHYDROCYCLOPENTA[b] INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS

Also Published As

Publication number Publication date
BR112017002449B1 (pt) 2022-08-09
CA2956514A1 (en) 2016-03-17
AU2018202714A1 (en) 2018-05-17
AU2018202714B2 (en) 2019-06-20
JP7349480B2 (ja) 2023-09-22
SG10201809673RA (en) 2018-12-28
JP6938550B2 (ja) 2021-09-22
AU2015315431A1 (en) 2017-03-09
WO2016040234A1 (en) 2016-03-17
ZA201802680B (en) 2020-08-26
KR20210083370A (ko) 2021-07-06
US20190111039A1 (en) 2019-04-18
EA201891008A2 (ru) 2018-09-28
AU2015315431B2 (en) 2018-03-08
EP3375444A1 (en) 2018-09-19
KR20180041268A (ko) 2018-04-23
JP2019089795A (ja) 2019-06-13
EA201790220A1 (ru) 2017-07-31
ES2779978T3 (es) 2020-08-21
TWI616201B (zh) 2018-03-01
MA45416A (fr) 2019-04-24
US20200390744A1 (en) 2020-12-17
IL258651A (en) 2018-06-28
US10799478B2 (en) 2020-10-13
MX391447B (es) 2025-03-21
CN106794178A (zh) 2017-05-31
CN113651797A (zh) 2021-11-16
US20240148694A1 (en) 2024-05-09
CA3067289A1 (en) 2016-03-17
IL279209B (en) 2022-10-01
US10758515B2 (en) 2020-09-01
IL279209A (en) 2021-01-31
TW201618782A (zh) 2016-06-01
NZ728612A (en) 2018-03-23
KR102024493B1 (ko) 2019-09-23
KR102619415B1 (ko) 2024-01-02
JP2022000432A (ja) 2022-01-04
MX373322B (es) 2020-05-21
MY195767A (en) 2023-02-10
EP3191094A1 (en) 2017-07-19
KR20220132669A (ko) 2022-09-30
US20170172992A1 (en) 2017-06-22
CA3067289C (en) 2023-04-04
CN113521068A (zh) 2021-10-22
IL250291B (en) 2020-09-30
EA034553B1 (ru) 2020-02-19
IL250291A0 (en) 2017-03-30
JP2023145479A (ja) 2023-10-11
AP2017009795A0 (en) 2017-03-31
MX2017003140A (es) 2017-05-23
MY198753A (en) 2023-09-23
JOP20180072A1 (ar) 2019-01-30
BR112017002449A2 (pt) 2017-12-05
JP2017527584A (ja) 2017-09-21
CA2956514C (en) 2023-04-18
KR20170040338A (ko) 2017-04-12
IL279209B2 (en) 2023-02-01
EP3191094B1 (en) 2020-02-19
KR20190015628A (ko) 2019-02-13
UA120099C2 (uk) 2019-10-10
IL258651B (en) 2021-02-28
JO3609B1 (ar) 2020-08-27
EA033606B1 (ru) 2019-11-08
HK1252811A1 (en) 2019-06-06
BR122018007412B1 (pt) 2022-08-23
CN108440497A (zh) 2018-08-24
SG11201701630VA (en) 2017-03-30
JP6893171B2 (ja) 2021-06-23
EA201891008A3 (ru) 2019-03-29
MX2021014120A (es) 2022-01-04

Similar Documents

Publication Publication Date Title
US20240148694A1 (en) Treatment of androgen deprivation therapy associated symptoms
HK1233508B (en) Treatment of androgen deprivation therapy associated symptoms
HK1233508A1 (en) Treatment of androgen deprivation therapy associated symptoms

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 18 APR 2018

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 18 APR 2018

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: OPKO HEALTH, INC.

Free format text: FORMER OWNER(S): ELI LILLY AND COMPANY

PC Assignment registered

Owner name: EIRGEN PHARMA LTD.

Free format text: FORMER OWNER(S): OPKO HEALTH, INC.